-
公开(公告)号：US20140012020A1
公开(公告)日：2014-01-09
申请号：US14017837
申请日：2013-09-04
Applicant: Bristol-Myers Squibb Company
Inventor： Omar D. Lopez , John A. Bender , Makonen Belema
IPC: C07D309/06
CPC classification number: C07D309/06 , A61K31/4178 , A61K45/06 , C07D405/14 , A61K2300/00
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
公开(公告)号：US20130183269A1
公开(公告)日：2013-07-18
申请号：US13735224
申请日：2013-01-07
Applicant: Bristol-Myers Squibb Company
Inventor： Piyasena Hewawasam , John F. Kadow , Omar D. Lopez , Nicholas A. Meanwell , Yong Tu , Alan Xiangdong Wang , Ningning Xu , Samayamunthula Venkata Satya Arun Kumar Gupta , Pothukanuri Srinivasu , Indasi Gopi Kumar , Ponugupati Suresh Kumar , Makonen Belema , Robert A. Fridell , Min Gao , Julie A. Lemm , Donald R. O'Boyle, II , Jin-Hua Sun , Chunfu Wang , Ying-Kai Wang
IPC: A61K31/4178 , A61K31/407 , A61K31/422 , A61K31/444 , A61K31/423 , A61K31/497 , A61K31/4545 , A61K31/498 , A61K31/506 , A61K31/5377 , A61K31/4709 , A61K31/437 , A61K31/519 , A61K31/428 , A61K31/501 , A61K31/55 , A61K31/496 , A61K31/4184 , A61K45/06 , C07D403/14 , C07D491/113 , A61K31/7056 , A61K38/21 , A61K38/05
CPC classification number: A61K31/4178 , A61K31/407 , A61K31/4184 , A61K31/422 , A61K31/423 , A61K31/428 , A61K31/437 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/497 , A61K31/498 , A61K31/501 , A61K31/506 , A61K31/519 , A61K31/5377 , A61K31/55 , A61K31/7056 , A61K38/05 , A61K38/21 , A61K38/212 , A61K38/217 , A61K45/06 , C07D403/14 , C07D491/113 , A61K2300/00
Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
-
公开(公告)号：US20130085147A1
公开(公告)日：2013-04-04
申请号：US13670691
申请日：2012-11-07
Applicant: Bristol-Myers Squibb Company
Inventor： Omar D. Lopez , Denis R. St. Laurent , Jason Goodrich , Jeffrey Lee Romine , Michael Serrano-Wu , Fukang Yang , Ramesh Kakarla , Xuejie Yang , Yuping Qiu , Lawrence B. Snyder
IPC: C07D471/04 , C07D249/12 , C07D417/14 , C07D403/14 , C07D263/32 , C07D413/14
CPC classification number: A61K31/415 , A61K31/4196 , A61K31/4245 , C07D231/12 , C07D233/58 , C07D233/64 , C07D249/06 , C07D249/08 , C07D249/12 , C07D263/32 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07D471/04
Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.
Abstract translation: 本公开一般涉及抗病毒化合物，更具体地涉及可以抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白的功能的化合物，包含这些化合物的组合物，以及用于抑制NS5A蛋白功能的方法。
-
公开(公告)号：US20130034520A1
公开(公告)日：2013-02-07
申请号：US13650374
申请日：2012-10-12
Applicant: Bristol-Myers Squibb Company
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Gan Wang , Lawrence G. Hamann
IPC: A61K31/4178 , C07D413/14 , A61K31/5377 , A61K31/496 , C07D401/14 , A61P31/14 , A61K38/05 , A61K38/21 , A61K31/7056 , A61K38/20 , A61K31/713 , C07D403/14 , A61K31/454
CPC classification number: C07D233/64 , A61K31/4178 , A61K45/06 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07F5/025 , C07F7/0812
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
公开(公告)号：US20180221342A1
公开(公告)日：2018-08-09
申请号：US15749557
申请日：2016-07-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： David B. Frennesson , Piyasena Hewawasam , Omar D. Lopez , Van N. Nguyen , Mark G. Saulnier , Yong Tu , Alan Xiangdong Wang , Gan Wang , Ningning Xu , Roshan Yadavrao Nimje , Hasibur Rahaman , Samayamunthula Venkata Satya Arun Kumar Gupta , Nicholas A. Meanwell , Makonen Belema
IPC: A61K31/4178 , A61P31/14
CPC classification number: A61K31/4178 , A61K31/417 , A61K31/4184 , A61K31/4439 , A61K31/497 , A61K31/7056 , A61K38/21 , A61K45/06 , A61K2300/00 , A61P31/14
Abstract: The present disclosure is generally directed to antiviral compounds, and more specifically directed to combinations of compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such combinations, and methods for inhibiting the function of the NS5A protein.
-
Patent Agency Ranking
公开(公告)号：US20150322031A1
公开(公告)日：2015-11-12
申请号：US14806964
申请日：2015-07-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Omar D. Lopez
IPC: C07D309/06
CPC classification number: C07D309/06 , A61K31/4178 , A61K31/4184 , A61K31/437 , A61K31/4375 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/4985 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Abstract translation: 本公开涉及用于治疗丙型肝炎病毒（HCV）感染的化合物，组合物和方法。 还公开了含有这些化合物的药物组合物和使用这些化合物治疗HCV感染的方法。
-
公开(公告)号：US08642025B2
公开(公告)日：2014-02-04
申请号：US13650374
申请日：2012-10-12
Applicant: Bristol-Myers Squibb Company
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. St. Laurent , Fukang Yang , David R. Langley , Lawrence G. Hamann
IPC: A61K31/454 , A61K31/713 , A61K31/4178 , A61K31/5377 , A61K31/496 , A61K31/7056 , A61K38/05 , A61K38/21 , A61K38/20 , A61P31/14 , C07D413/14 , C07D401/14 , C07D403/14
CPC classification number: C07D233/64 , A61K31/4178 , A61K45/06 , C07D207/16 , C07D401/14 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/14 , C07F5/025 , C07F7/0812
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
Abstract translation: 本公开涉及用于治疗丙型肝炎病毒（HCV）感染的化合物，组合物和方法。 还公开了含有这些化合物的药物组合物和使用这些化合物治疗HCV感染的方法。
-
公开(公告)号：US20140018389A1
公开(公告)日：2014-01-16
申请号：US14027531
申请日：2013-09-16
Applicant: Bristol-Myers Squibb Company
Inventor： Rico Lavoie , John A. Bender , Jeffrey Lee Romine , Edward H. Ruediger , Carol Bachand , Omar D. Lopez , Qi Chen , Makonen Belema , John F. Kadow , Lawrence G. Hamann
IPC: C07D417/14 , C07D405/14 , C07D401/14 , C07D403/14 , C07D409/14 , C07D413/14
CPC classification number: C07D417/14 , C07D401/14 , C07D403/06 , C07D403/10 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/10 , C07D419/10 , C07D493/08
Abstract: This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.
Abstract translation: 本公开涉及式（I）的新化合物或说明书中定义的和包含这些新化合物的组合物。 这些化合物是有用的抗病毒剂，特别是抑制由丙型肝炎病毒（HCV）编码的NS5A蛋白的功能。 因此，本公开还涉及通过使用这些新化合物或包含这些新化合物的组合物治疗HCV相关疾病或病症的方法。
-
公开(公告)号：US20130280211A1
公开(公告)日：2013-10-24
申请号：US13919027
申请日：2013-06-17
Applicant: Bristol-Myers Squibb Company
Inventor： Carol Bachand , Makonen Belema , Daniel H. Deon , Andrew C. Good , Jason Goodrich , Clint A. James , Rico Lavoie , Omar D. Lopez , Alain Martel , Nicholas A. Meanwell , Van N. Nguyen , Jeffrey Lee Romine , Edward H. Ruediger , Lawrence B. Snyder , Denis R. ST. Laurent , Fukang Yang , David R. Langley , Lawrence G. Hamann
IPC: C07D403/14 , C07D401/14 , A61K45/06 , A61K31/5377 , C07F7/10 , A61K31/695 , A61K31/4178 , A61K31/4545
CPC classification number: C07D403/14 , A61K31/4178 , A61K31/4545 , A61K31/5377 , A61K31/695 , A61K45/06 , C07D401/14 , C07F7/10
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
公开(公告)号：US09776981B2
公开(公告)日：2017-10-03
申请号：US14807084
申请日：2015-07-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Rico Lavoie , John A. Bender , Zhong Yang , Makonen Belema , Omar D. Lopez , Qi Chen , Gan Wang , Piyasena Hewawasam
IPC: C07D487/04 , C07D309/06 , C07D401/14 , C07D403/14 , C07D471/04 , A61K31/4178 , A61K31/4184 , A61K31/437 , A61K31/4375 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/4985 , A61K31/5377 , A61K45/06 , C07D403/10 , C07D405/14 , C07D413/14
CPC classification number: C07D309/06 , A61K31/4178 , A61K31/4184 , A61K31/437 , A61K31/4375 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/4985 , A61K31/5377 , A61K45/06 , C07D401/14 , C07D403/10 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/04 , C07D487/04
Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.056 seconds)
